Citations

Clear

163 citation(s) found for "Sharp, H L".

Do research participants share genomic screening results with family members?
Wynn, Julia , Rasouly, Hila Milo , Vásquez‐Loarte, Tania , Saami, Akilan M. , Weiss, Robyn, Ziniel, Sonja I. , Appelbaum, Paul S. , Fasel, David , Harr, Margaret , Hoell, Christin , Leppig, Kathleen A. , Myers, Melanie F. , Perez, Emma , Prows, Cynthia A. , Sharp, Richard R. , Smith, Maureen E. , Wiesner, Georgia L. , Williams, Janet L. , Zawatsky, Carrie L. Blout , Gharavi, Ali G. , Pacyna, Joel E. , Myers, Melanie F , Sharp, Richard R , Appelbaum, Paul , Milo Rasouly, Hila , Hoell, Christin , Clayton, Ellen Wright , Christensen, Kurt D. , Green, Robert C. , Hain, Heather S. , Kullo, Iftikhar J. , Rahm, Alanna Kulchak , Campbell‐Salome, Gemme , Chung, Wendy K. , Holm, Ingrid A.

Mayo Clinic

Journal of Genetic Counseling | October 21, 2021 | Volume: 31 | Issue: 2 | Pages: 447-458

10.1002/jgc4.1511 | PMID 34665896 Get It

Abstract The public health impact of genomic screening can be enhanced by cascade testing. However, cascade testing depends on communication of results to family members. While the barriers and facilitators of family communication have been researched following clinical genetic testing, the factors impacting the dissemination of genomic screening results are unknown. Using the pragmatic Electronic Medical Records and Genomics Network‐3 (eMERGE‐3) study, we explored the reported sharing practices of participants who underwent genomic screening across the United States. Six eMERGE‐3 sites returned genomic screening results for mostly dominant medically actionable disorders and surveyed adult participants regarding communication of results with first‐degree relatives. Across the sites, 279 participants completed a 1‐month and/or 6‐month post‐results survey. By 6 months, only 34% of the 156 respondents shared their results with all first‐degree relatives and 4% did not share with any. Over a third (39%) first‐degree relatives were not notified of the results. Half (53%) of participants who received their results from a genetics provider shared them with all first‐degree relatives compared with 11% of participants who received their results from a non‐genetics provider. The most frequent reasons for sharing were a feeling of obligation (72%) and that the information could help family members make medical decisions (72%). The most common reasons indicated for not sharing were that the family members were too young (38%), or they were not in contact (25%) or not close to them (25%). These data indicate that the professional returning the results may impact sharing patterns, suggesting that there is a need to continue to educate healthcare providers regarding approaches to facilitate sharing of genetic results within families. Finally, these data suggest that interventions to increase sharing may be universally effective regardless of the origin of the genetic result.
Values and other decisional factors regarding treatment of hypercalcaemia of malignancy: a systematic review protocol
Rahme, Maya , Piggott, Thomas , Hneiny, Layal , Fuleihan, Ghada El‐Hajj , El-Hajj Fuleihan, Ghada , Piggott, Thomas , Bassatne, Aya , Murad, M. Hassan

Mayo Clinic

BMJ Open | October 11, 2021 | Volume: 11 | Issue: 10 | Pages: e051141

10.1136/bmjopen-2021-051141 | PMID 34635523 Get It

Introduction Hypercalcaemia of malignancy (HCM) is the second most common cause of hypercalcaemia and is associated with significant morbidity and mortality. Several treatment options are available including pharmacological therapy with bisphosphonates, denosumab, glucocorticoids and calcimimetics, as well as conventional therapy with hydration and possibly calcitonin. While guidelines have previously considered treatment effects, no guideline has yet considered a range of contextual factors impacting recommendations for the management. The aim of this study was to summarise the available evidence on important decisional factors for the development of guidelines for the treatment of HCM. These include patient’s values and preferences, cost, acceptability, feasibility and equity. Methods and analysis This protocol is registered in PROSPERO (registration number: CRD42021264371). This is a systematic review of observational studies, case series, trials, reviews and qualitative studies involving treatment of adult patients with HCM. We will develop and execute two independent search strategies using five databases: PubMed, Medline (OVID), Embase.com, CINAHL (EBSCO) and Cochrane, and review their combined output. Two reviewers will screen titles and abstracts and full texts and will implement data abstraction from relevant studies independently and in duplicate. The outcomes of interest are the decisional factors that influence drug selection, with possible subgroup summaries by drug class or aetiology of HCM. We will present the data collected in a narrative and thematic approach. Ethics and dissemination Ethical approval is not applicable for our study, since we will only collect data from available literature. This systematic review will be submitted to a peer-reviewed journal when completed.
Beyond the Belmont Report
Siddiqui, Wamia , Sharp, Richard R. , Sharp, Richard R

Mayo Clinic

The American Journal of Bioethics | September 23, 2021 | Volume: 21 | Issue: 10 | Pages: 1-4

10.1080/15265161.2021.1972649 | PMID 34554060 Get It

Factors that Influence Intent to Share Genetic Information Related to Cancer Risk with Family Members
Finn, Kelsey Stuttgen , Pacyna, Joel E. , Tsou, Cindy Azevedo, Samadder, N. Jewel , Sharp, Richard R. , Stuttgen, Kelsey , Tsou, Cindy, Samadder, Niloy J, Sharp, Richard R

Mayo Clinic

Journal of Health Communication | September 2, 2021 | Volume: 26 | Issue: 8 | Pages: 545-552

10.1080/10810730.2021.1968078 | PMID 34473010 Get It

The treatment of anogenital extramammary Paget's disease as part of a multidisciplinary approach: The use of Mohs surgery moat method with CK7
Brough, Kevin, Carley, Sama K. , Vidal, Nahid Y.

Mayo Clinic

International Journal of Dermatology | August 26, 2021 | Volume: 61 | Issue: 2 | Pages: 238-245

10.1111/ijd.15847 | PMID 34435670 Get It

Abstract Although most cases of extramammary Paget's disease (EMPD) are localized to the intraepidermal, the extensive subclinical extension can lead to high rates of marginal recurrence with wide local excisions and topically destructive treatments. Recurrence rates of EMPD treated with Mohs micrographic surgery (MMS) without immunohistochemical staining are better but variable. Here, we describe our multidisciplinary approach for treating large EMPD tumors of the anogenital region involving critical anatomy using MMS for peripheral margin clearance (moat method) and intraoperative CK7 immunostaining. Our clinical pearls for the management of anogenital EMPD are based on 53 multidisciplinary cases treated at the author's institution between 2014 and 2020.
Electronic charting of radiation therapy planning and treatment: Report of Task Group 262
Santos, Luis E. Fong de los, Fontenla, Sandra, Hanley, Joseph, Harwalkar, Vijay A., Hong, Linda , Huang, Y. Jessica , Kim, Grace Gwe‐Ya, Richardson, Susan , Sutlief, Steven , Yaddanapudi, Sridhar , Merkel, Sue, Parry, Mark D., Fong de Los Santos, Luis E, Parry, Mark, Yaddanapudi, Sridhar , Mechalakos, James , Dieterich, Sonja , Kim, Grace Gwe‐Ya

Mayo Clinic

Medical Physics | July 20, 2021 | Volume: 48 | Issue: 11 | Pages: No page available

10.1002/mp.15116 | PMID 34287961 Get It

AbstractWhile most Radiation Oncology clinics have adopted electronic charting in one form or another, no consensus document exists that provides guidelines for safe and effective use of the Radiation Oncology electronic medical records (RO‐EMR). Task Group 262 was formed to provide these guidelines as well as to provide recommendations to vendors for improving electronic charting functionality in future. Guidelines are provided in the following areas: Implementation and training for the RO‐EMR, acceptance testing and quality assurance (QA) of the RO‐EMR, use of the RO‐EMR as an information repository, use of the RO‐EMR as a workflow manager, electronic charting for brachytherapy and nonstandard treatments, and information technology (IT) considerations associated with the RO‐EMR. The report was based on a literature search by the task group, an extensive survey of task group members on their respective RO‐EMR practices, an AAPM membership survey on electronic charting, as well as group consensus.
Vitamin D3 Dose Requirement That Raises 25-Hydroxyvitamin D to Desirable Level in Overweight and Obese Elderly
Bacha, Dania S. , Rahme, Maya , Al‐Shaar, Laila , Halaby, Georges, Mahfoud, Ziyad , Habib, Robert, Arabi, Asma , Fuleihan, Ghada El‐Hajj , El-Hajj Fuleihan, Ghada , Baddoura, Rafic , Singh, Ravinder J.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | May 6, 2021 | Volume: 106 | Issue: 9 | Pages: e3644-e3654

10.1210/clinem/dgab296 | PMID 33954783 Get It

Abstract Context Guidelines for the dosage of vitamin D supplementation vary widely globally. Objective To investigate the impact of 2 vitamin D doses, bracketed between the IOM recommended dietary allowance (RDA) and the upper tolerable limit, on vitamin D nutritional status in elderly individuals. Methods This post hoc analysis of data collected from a 12-month, double-blind, randomized control trial included 221 ambulatory participants (≥ 65 years) with a mean BMI of 30.2 kg/m2 and a mean baseline serum 25-hydroxyvitamin D [25(OH)D] level of 20.4 ± 7.4 ng/mL, who were recruited from 3 outpatient centers in Lebanon. All participants received 1000 mg of elemental calcium daily from calcium citrate plus the daily equivalent of either 600 IU or 3750 IU of vitamin D3. Results Mean 25(OH)D level at 12 months was 26.0 ng/mL with low dose and 36.0 ng/mL with high dose vitamin D3. The proportion of participants reaching a value ≥ 20 ng/mL was 86% in the low dose, and 99% in the high dose arms, with no gender differences. The increment of 25(OH)D per 100 IU/day was 1 ng/mL with the low dose, and 0.41 ng/mL with the high dose. Serum 25(OH)D levels at 1 year were highly variable in both treatment arms. Baseline 25(OH)D level and vitamin D dose—but not age, BMI, gender, or season—were significant predictors of serum 25(OH)D level post-intervention. Conclusion The IOM Recommended Dietary Allowance (RDA) of 600 IU/day does not bring 97.5% of ambulatory elderly individuals above the desirable threshold of 20 ng/mL. Country-specific RDAs are best derived taking into account the observed variability and predictors of achieved 25(OH)D levels.
“Who Doesn’t Like Receiving Good News?” Perspectives of Individuals Who Received Genomic Screening Results by Mail
Beck, Annika T., Sutton, Erica J., Chow, Carolyn , Curtis, Susan , Sharp, Richard R. , Chow, Carolyn P Y, Curtis, Susan H , Sharp, Richard R , Kullo, Iftikhar J.

Mayo Clinic

Journal of Personalized Medicine | April 21, 2021 | Volume: 11 | Issue: 5 | Pages: 322

10.3390/jpm11050322 | PMID 33919001 Get It

As genomic sequencing expands to screen larger numbers of individuals, offering genetic counseling to everyone may not be possible. One approach to managing this limitation is for a genetic counselor to communicate clinically actionable results in person or by telephone, but report other results by mail. We employed this approach in a large genomic implementation study. In this paper, we describe participants’ experiences receiving genomic screening results by mail. We conducted 50 semi-structured telephone interviews with individuals who received neutral genomic screening results by mail. Most participants were satisfied receiving neutral results by mail. Participants generally had a good understanding of results; however, a few participants had misunderstandings about their genomic screening results, including mistaken beliefs about their disease risk and the comprehensiveness of the test. No one reported plans to alter health behaviors, defer medical evaluations, or take other actions that might be considered medically problematic. Reporting neutral results by mail is unlikely to cause recipients distress or generate misunderstandings that may result in reduced vigilance in following recommended preventive health strategies. Nonetheless, some individuals may benefit from additional genetic counseling support to help situate their results in the context of personal concerns and illness experiences.
Prophylactic Drainage after Appendectomy for Perforated Appendicitis in Adults: A Post Hoc Analysis of an EAST Multi-Center Study
Qian, Sinong , Vasileiou, Georgia , Pust, Gerd Daniel , Zakrison, Tanya L. , Rattan, Rishi , Zielinski, Martin D. , Ray-Zack, Mohamed D. , Group, on behalf of the EAST Appendicitis Study, Alouidor, Reginald, Hing, Kailyn Kwong, Sharp, Victoria , Serena, Thomas , Kasotakis, George , Perez, Sean, Allmond, Stacie L., Long, Bruce, Barth, Nadine, Roman, Janika San, Lawless, Ryan A. , Cralley, Alexis , Gelbard, Rondi B. , Szczepanski, Crystal, Eyer, Steven D., Proulx, Kaitlyn, Wild, Jeffrey, Young, Katelyn , Teicher, Erik J. , Lita, Elena, Morris, David S. , Juarez, Laura, Catalano, Richard D., Turay, David, Roberts, Jennifer C., Kaafarani, Haytham M.A., Eid, Ahmed , Kanaan, Tala , Portillo, Victor, Collom, Morgan, Eddine, Savo Bou Zein , Tabrizi, Maryam B. , Elsharkawy, Ahmed Elsayed Mohammed , Yeh, D. Dante, Evans, David , Vázquez, Daniel , Saxe, Jonathan M. , Jacobson, Lewis E. , Behrens, Brandon, Joseph, Bellal , Mull, Jennifer, Pasley, Jason, O’Meara, Lindsay , Gök, Ali , To, Jocelyn, Bradley, Matthew J. , Zielinski, Martin, Zeeshan, Muhammad , Namias, Nicholas , Yeh, D. Dante , Group, on behalf of the EAST Appendicitis Study, Morris, David, Cullinane, Daniel C. , Roberts, Jennifer C., Dodgion, Christopher M. , Yeh, D. Dante, Vazquez, Daniel E., Schreiber, Martin J. , Nahmias, Jeffry T. , Sun, Beatrice J. , Crandall, Marie , Rodríguez, Carlos

Mayo Clinic

Surgical Infections | April 20, 2021 | Volume: 22 | Issue: 8 | Pages: 780-786

10.1089/sur.2019.258 | PMID 33877912 Get It

Integrating Genomic Screening into Primary Care: Provider Experiences Caring for Latino Patients at a Community-Based Health Center
Srinivasan, Tarika , Sutton, Erica J., Beck, Annika T., Cuellar, Idali, Hernandez, Valentina, Pacyna, Joel E. , Shaibi, Gabriel Q. , Lindor, Noralane M. , Sharp, Richard R. , Sharp, Richard R , Kullo, Iftikhar J. , Singh, Davinder

Mayo Clinic

Journal of Primary Care & Community Health | March 17, 2021 | Volume: 12 | Issue: No issue available | Pages: No page available

10.1177/21501327211000242 | PMID 33729042 Get It

Introduction: Minority communities have had limited access to advances in genomic medicine. Mayo Clinic and Mountain Park Health Center, a Federally Qualified Health Center in Phoenix, Arizona, partnered to assess the feasibility of offering genomic screening to Latino patients receiving care at a community-based health center. We examined primary care provider (PCP) experiences reporting genomic screening results and integrating those results into patient care. Methods: We conducted open-ended, semi-structured interviews with PCPs and other members of the health care team charged with supporting patients who received positive genomic screening results. Interviews were recorded, transcribed, and analyzed thematically. Results: Of the 500 patients who pursued genomic screening, 10 received results indicating a genetic variant that warranted clinical management. PCPs felt genomic screening was valuable to patients and their families, and that genomic research should strive to include underrepresented minorities. Providers identified multiple challenges integrating genomic sequencing into patient care, including difficulties maintaining patient contact over time; arranging follow-up medical care; and managing results in an environment with limited genetics expertise. Providers also reflected on the ethics of offering genomic sequencing to patients who may not be able to pursue diagnostic testing or follow-up care due to financial constraints. Conclusions: Our results highlight the potential benefits and challenges of bringing advances in precision medicine to community-based health centers serving under-resourced populations. By proactively considering patient support needs, and identifying financial assistance programs and patient-referral mechanisms to support patients who may need specialized medical care, PCPs and other health care providers can help to ensure that precision medicine lives up to its full potential as a tool for improving patient care.